Background 22 Because human epidermal growth factor-like receptor (HER) 2 is expressed on the surface of 23 human pancreatic carcinoma cells to varying degrees, trastuzumab, an anti-HER2 monoclonal 24 antibody (mAb), is expected to exert antibody-dependent, natural killer (NK) cell-mediated 25 cytotoxicity (ADCC) against the cells. However, some reports found that the effect of 26 trastuzumab against human pancreatic carcinoma cells was limited because most express only 27 limited HER2.
to 40-fold amounts of NK cells for 4 h at 37°C. Anti-CD137 mAb 10 g/ml was added to some 136 wells to examine whether it could enhance Tmab-induced ADCC. After incubation, the plates 137 were centrifuged for 1 min at 1000 rpm, and culture supernatants were collected for 138 cytotoxicity assays and cytokine titration assays. The cells were harvested and used for 139 evaluation of the kinetics of cell surface molecules. The FcRIIIA polymorphism of NK cells was evaluated according to the previous reports 154 [36, 37] . In brief, freshly isolated NK cells were harvested and stained separately with two anti- Cytotoxicity assay 163 The CytoTox 96 nonradioactive cytotoxicity assay kit (Promega, Madison, WI) was used 164 for evaluating NK cell cytotoxicity according to the manufacturer's instructions. In brief, 5  165 10 3 treated target cells were resuspended in 50 l of assay medium and placed in a 96-well 166 round-bottom culture plate. Ten-to 40-fold amounts of NK cells suspended in 50 l of assay 167 medium were added to each well and also sheeted in empty wells to measure the spontaneous 168 lysis of effector cells. Lysis solution 50 l and assay medium 50 l were sheeted in another 169 well for measurement of maximal and minimal lysis. The plate was centrifuged at 250 g for 4 170 min and incubated for 4 h at 37°C. Lysis solution 10 l was added to each well 45 min before 171 the end of incubation. The plate was centrifuged again for 4 min at 250 g, and then culture against the HER2-low-expressing pancreatic cancer cell line. A previous report showed that 268 Tmab-mediated ADCC against HER2-expressing human breast cancer cell lines was about 269 30% when they were exposed to a 20-fold amount of allogeneic NK cells [40] . Compared with 270 that report, the cytotoxicity of Tmab plus CD137 mAb-mediated ADCC against the HER2- low-expressing human pancreatic cancer. 281 We also found that the binding affinity of FcRIIIA to IgG-Fc is strongly associated with 282 the expression of CD137 on the surface of NK cells along with its activation after stimulation 283 with Tmab. Previous reports showed that the FcRIIIA polymorphism is closely associated with Tmab increased more in VV/VF than in FF individuals, and there was no significant 303 increase in the production of these cytokines after the addition of CD137 mAb. The reason 304 why activated, CD137-expressing NK cells did not secrete higher levels of cytokines after 
